N83 High risk clinical stage A nonseminomatous testicular tumors: Primary retroperitoneal lymphadenectomy or cisplatin-based chemotherapy?

2009 ◽  
Vol 8 (8) ◽  
pp. 597
Author(s):  
D. Argirovic ◽  
A. Argirovic
Keyword(s):  
High Risk ◽  
Clinical Stage ◽  
Testicular Tumors ◽  
Retroperitoneal Lymphadenectomy ◽  
Primary Retroperitoneal

scholarly journals Embryonal carcinoma of an intraabdominal testicular tumor on an undescended testicle: a case report

2020 ◽  
Author(s):  
Mihai Domnutiu Suciu ◽  
Nucu Alexandru Marica ◽  
Traian Oniu ◽  
Andrei Ionut Tomuta ◽  
Radu Badea
Keyword(s):  
High Risk ◽  
Embryonal Carcinoma ◽  
Testicular Tumor ◽  
Surgical Excision ◽  
Testicular Tumors ◽  
Retroperitoneal Lymphadenectomy ◽  
Left Testicle ◽  
Lymphnode Metastasis ◽  
Risk Of Malignancy ◽  
Histological Result

Cryptorchidism, as a singular pathology or associated with other dysgenesis syndromes, is one of the main factors of risk for the development of the testicular tumors. Although there are a great number of cases of undescended testicles that are diagnosed and treated during the first 6-12 months of life, there are rare cases of adults who are undiagnosed and untreated from this anomaly, which can present a high risk of malignancy . In this study we present the case of a 36-year-old patient, diagnosed at puberty with left cryptorchidism, untreated, who also hadevidenced a large intraabdominal tumoral mass associated with it. The tumoral mass had its origin in the undescended left testicle. Surgical excision of the tumor and retroperitoneal lymphadenectomy was performed. The histological result revealed embryonal carcinoma, without lymphnode metastasis. Adult patients with untreated cryptorchidism should be thoroughly investigated, as they have a high risk of developing testicular cancer.

Comparison between clinical and pathological staging in low stage non-seminomatous germ cell testicular tumors

1992 ◽  
Vol 59 (1_suppl) ◽  
pp. 166-169
Author(s):  
N. Nicolai ◽  
G. Pizzocaro ◽  
R. Salvioni
Keyword(s):  
Germ Cell ◽  
Clinical Stage ◽  
Serum Markers ◽  
Stage I ◽  
Stage Ii ◽  
Clinical Staging ◽  
Testicular Tumors ◽  
Retroperitoneal Lymphadenectomy ◽  
Magnetic Resonance Imaging Mri ◽  
Negative Imaging

Between January 1985 and December 1990, 208 consecutive patients underwent retroperitoneal lymphadenectomy (RPLND) for low-stage (negative imaging or retroperitoneal disease up to 3 cm) non-seminomatous germ cell testicular tumors. Before RPLND, patients were staged with computed tomography (CT) or magnetic resonance imaging (MRI) of abdomen and pelvis, alpha-fetoprotein (AFP) and beta submit of human chorionic gonadotropin (b-HCG) assay. Lymphangiography (LAG) was performed in 139 cases. Out of 208, 173 (83%) patients belonged to clinical stage I, 21 (10%) to clinical stage II-A (retroperitoneal disease up to 2 cm) and 14 (7%) to clinical stage ll-B (retroperitoneal disease from 2 to 3 cm). Before RPLND, serum markers AFP and b-HCG were pathological in 16 (9%) of 173 patients in clinical stage I, in 7 (33%) of 21 in clinical stage ll-A and in 6 (43%) of 14 in clinical stage ll-B < 3 cm. Retroperitoneal metastases were pathologically found in 46 (27%) of 173 patients in clinical stage I, in 15 (71%) of 21 in clinical stage ll-A and in all 14 clinical stage ll-B < 3 cm. As many as 31 (20%) of 157 in clinical stage I with negative markers and only 8 (57%) of 14 clinical stage II-A with negative markers had retroperitoneal metastases. The low reliability of clinical staging enforces RPLND as the most accurate staging procedure for marker negative clinical stage I and II-A patients.

Leydig cell tumors: Prognostic factors

1992 ◽  
Vol 59 (1_suppl) ◽  
pp. 163-165 ◽  
Author(s):  
R. Casagrande ◽  
F. Di Tonno ◽  
G. Capizzi ◽  
G. Costa ◽  
W. Artibani ◽  
...  
Keyword(s):  
Leydig Cell ◽  
Clinical Stage ◽  
Stage I ◽  
Conventional Chemotherapy ◽  
Testicular Tumors ◽  
Tumor Spread ◽  
Retroperitoneal Lymphadenectomy ◽  
Pathological Analysis ◽  
Leydig Cell Tumors

Leydig Cell Tumors (LCT) are uncommon testicular neoplasms that account for 1 to 3% of all testicular tumors. Only about 10% of LCT are malignant and generally refractory to radiotherapy and conventional chemotherapy. Therefore, there is some debate about the value of Retroperitoneal Lymphadenectomy (RPLND) in Stage I disease. Indeed, although surgery is the only available therapy which is able to cure and prevent tumor spread, RPLND is a challenging invasive surgery and may be useless in 90% of the cases. The Authors observed 5 cases of patients in clinical Stage I disease with benign behaviour demonstrated after an adequate follow-up. Pathological analysis showed absence of signs of malignancy. Starting from these experiences, it is suggested that RPLND may be avoided in selected cases when definite pathological signs of malignancy are absent.

Sign in / Sign up

Export Citation Format

Share Document